NeuroSense Therapeutics Ltd. financial data

Symbol
NRSN, NRSNW on Nasdaq
Industry
Pharmaceutical Preparations
Location
11 Hamenofim St., Building B, Herzliya, Israel
State of incorporation
Israel
Fiscal year end
December 31
Latest financial report
20-F - Q4 2024 - Apr 7, 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.2M shares +51%
Common Stock, Shares, Outstanding 23.2M shares +51%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.38M USD +28%
Assets, Current 4.4M USD +51%
Property, Plant and Equipment, Net 66K USD -22.4%
Operating Lease, Right-of-Use Asset 84K USD -48.1%
Assets 4.58M USD +43.6%
Employee-related Liabilities, Current 498K USD -66.4%
Liabilities, Current 1.99M USD -42.4%
Operating Lease, Liability, Noncurrent 36K USD
Liabilities 1.99M USD -59.7%
Retained Earnings (Accumulated Deficit) -36.7M USD -40.3%
Stockholders' Equity Attributable to Parent 2.58M USD
Liabilities and Equity 4.58M USD +43.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 90M shares +50%
Common Stock, Shares, Issued 23.2M shares +51%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.38M USD +28%
Deferred Tax Assets, Valuation Allowance 7.13M USD +47.7%
Deferred Tax Assets, Gross 7.15M USD +47%
Operating Lease, Liability 73K USD +5.8%
Lessee, Operating Lease, Liability, to be Paid 75K USD -50.7%
Property, Plant and Equipment, Gross 126K USD +2.44%
Operating Lease, Liability, Current 73K USD +5.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 78K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 75K USD +1.35%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2K USD -80%
Deferred Tax Assets, Operating Loss Carryforwards 5.69M USD +71.6%
Deferred Tax Assets, Net of Valuation Allowance 7.13M USD +47.7%